The sales of Modulators of the Genital System and Sex Hormones in Sweden are forecasted to grow steadily from 118.2 million USD PPP in 2024 to 122.9 million USD PPP in 2028. This reflects a consistent year-on-year growth, with the value increasing each year. To illustrate, between 2024 and 2025, there is a 1.01% increase, 1.00% increase from 2025 to 2026, 0.91% from 2026 to 2027, and a 0.99% increase from 2027 to 2028.
Reviewing data from 2022 to 2023, we observe the last two years' variation not provided in the dataset. However, the Compound Annual Growth Rate (CAGR) over the five years from 2024 to 2028 is estimated, showcasing a consistent upward trend.
Future trends to watch for include the potential impact of technological advancements in pharmaceuticals, regulatory changes, demographic shifts, and economic factors influencing healthcare spending in Sweden. Additionally, the introduction of new therapies and potential generic competition might affect market dynamics.
